• 1
    Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005; 1: 44.
  • 2
    Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003; 18(Suppl. 6): 68.
  • 3
    Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18: 1260.
  • 4
    Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878.
  • 5
    Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574.
  • 6
    Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34: 1048.
  • 7
    Weiner GJ, Link BK. Antibody therapy of lymphoma. Adv Pharmacol 2004; 51: 229.
  • 8
    Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456.
  • 9
    Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005; 4: 526.
  • 10
    Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9: 408.
  • 11
    Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621.
  • 12
    Pinto J, Lacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32: 83.
  • 13
    Briggs WA, Gimenez LF, Samaniego-Picota M, et al. Relationship between lymphocyte and clinical steroid responsiveness in focal segmental glomerulosclerosis. J Clin Pharmacol 2000; 40: 115.
  • 14
    Herve C, Dantal J. Possible new perspectives for our understanding of nephrotic syndrome recurrence. Nephrol Dial Transplant 2006; 21: 10.
  • 15
    Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5: 1179.
  • 16
    Laufer J, Ettenger RB, Ho WG, Cohen AH, Marik JL, Fine RN. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46: 540.
  • 17
    Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7.
  • 18
    Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41: 1314.
  • 19
    Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 78.
  • 20
    Skhiri H, Morelon E, Noel LH, et al. Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transpl Int 2005; 18: 458.
  • 21
    Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003; 75: 810.
  • 22
    Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004; 44: 50.
  • 23
    Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19: 794.
  • 24
    Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. New Engl J Med 2006; 354: 1962.
  • 25
    Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660.
  • 26
    Hristea D, Hadaya K, Marangon N, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20: 102.
  • 27
    Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859.
  • 28
    Youinou P, Hillion S, Jamin C, Pers JO, Saraux A, Renaudineau Y. B lymphocytes on the front line of autoimmunity. Autoimmun Rev 2006; 5: 215.
  • 29
    Cohen CD, Calvaresi N, Armelloni S, et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005; 18: 328.
  • 30
    Hippen BE, DeMattos A, Cook WJ, Kew CE 2nd, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248.